Hematologic Malignancy
B Lymphoblastic Leukemia/Lymphoma
CI-CAN-00000469Explore in graph →
Hematologic163 active trials1 approved drugs180 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000469Explore in graph →
Variants & evidence
296 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL2 Fusion1 | ||||||||
| (oncogenic) | B Acute Lymphoblastic LeukemiaALIAS | Oncogenic | C | Supports Oncogenicity | 1 | submitted | EID12493In a study of 176 ALL patients, consisting of 136 B- and 40 T-lineage, multiplex nested RT-PCR was used to look for ETV6 fusions. One patient had ETV6::ABL2 fusion. Patient was a 17 year old with kary… (full text at CIViC) PMID 22373549 · Zhou et al., 2012 · Open in CIViC | civic |
| JAK2 Fusion3 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 4 | accepted | EID8102In this study which included 1389 cases of high-risk pediatric B-ALL, 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on CRLF2 n… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | accepted | EID7696In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on … (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports | ||||
| NTRK3 Fusion6 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 1 | submitted | EID12295Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterised by genomic alterations that activate cytokine receptor and kinase signaling. The author e… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC | civic |
| (oncogenic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 4 | accepted | EID8931The tyrosine kinase domain of NTRK3 was inserted into exon 6 of Etv6 to create conditional knock-in Etv6-NTRK3 mice . Expression was induced in pre-b cells during lymphoid development by CD19-Cre. Fus… (full text at CIViC) PMID 29880614 · Roberts et al., 2018 · Open in CIViC | civic |
| Larotrectinib | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | |||||||
| RUNX1 Fusion4 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1ALIAS | Diagnostic | A | Supports Positive | 5 | accepted | EID8599ETV6-RUNX1 rearranged leukemia is a well established diagnostic entity in the WHO classification of leukemia. It is designated as B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUN… (full text at CIViC) PMID 27069254 · Arber et al., 2016 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1ALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12293In this study, the authors investigated the role of the ETV6::RUNX1 fusion in the diagnosis of B-lymphoblastic leukemia/lymphoma. B-ALL is a heterogeneous disease, and identifying cytogenetic abnormal… (full text at CIViC) PMID 9226156 · Borkhardt et al., 1997 · Open in CIViC | civic |
| 〃 | ||||||||
| EZH2 A692V1 | ||||||||
| GSK126 | B Acute Lymphoblastic LeukemiaALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11707The A687V EZH2-mutant SUP-B8 B-ALL cell line exhibited the greatest sensitivity to EZH2 inhibitor (GSK126) compared to 7 other EZH2 wild-type B-ALL cell lines by cell proliferation assay. The increase… (full text at CIViC) PMID 25253781 · Ott et al., 2014 · Open in CIViC | civic |
| PDGFRA Fusion3 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 3 | submitted | EID13331In a 10-year-old female diagnosed with B-lymphoblastic leukemia/lymphoma (B-LL/B-ALL), FISH analysis identified a CHIC2 deletion, suggestive of a FIP1L1::PDGFRA fusion, which was subsequently confirme… (full text at CIViC) PMID 39996417 · Nunn et al., 2025 · Open in CIViC | civic |
| Chemotherapy + ImatinibCombination | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID12565A 10‐year‐old female patient presented with pancytopenia and normal eosinophils and had the diagnosis of B‐lymphoblastic leukemia/lymphoma. FISH identified a CHIC2 deletion, suggestive of FIP1L1::PDG… (full text at CIViC) PMID 39996417 · Nunn et al., 2025 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | |||||||
| FLT3 I8361 | ||||||||
| (prognostic) | B Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A RearrangedALIAS | Prognostic | B | Supports Poor Outcome | 2 | submitted | EID8926In this study, 162 pediatric ALL patients (50 infants younger than 11 months and 112 children older than 1 year (93 B-cell precursors, 19 T-cell phenotypes)—in addition to 81 healthy donors were analy… (full text at CIViC) PMID 14504097 · Taketani et al., 2004 · Open in CIViC | civic |
| FLT3 Overexpression1 | ||||||||
| Sunitinib | Adult B Acute Lymphoblastic LeukemiaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1528A 25-year-old Caucasian male presented with a second relapse of B-ALL. RNA sequencing revealed FLT3 overexpression (also confirmed by IHC). The patient was treated with 22 days of sunitinib, permittin… (full text at CIViC) PMID 27181063 · Griffith et al., 2016 · Open in CIViC | civic |
| ABL1 Fusion5 | ||||||||
| (oncogenic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Oncogenic | C | Supports Oncogenicity | 2 | accepted | EID7253In a 16-year old Caucasian female with B-lymphoblastic leukemia (B-ALL), the t(3;9)(p12;q34) was identified by cytogenetic studies. 5'RACE PCR detected the in-frame FOXP1::ABL1 (exon 19::exon 4) fusio… (full text at CIViC) PMID 21391972 · Ernst et al., 2011 · Open in CIViC | civic |
| (prognostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Prognostic | C | Supports Poor Outcome | 1 | accepted | EID7651The FOXP1::ABL1 fusion was identified in a male patient in a Dutch/German cohort of 77 BCR::ABL1-like cases. The FOXP1::ABL1 fusion was confirmed by PCR and targeted ligation amplification, and was fo… (full text at CIViC) PMID 27894077 · Boer et al., 2017 · Open in CIViC | civic |
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | ||||
| KIT Fusion1 | ||||||||
| (oncogenic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Oncogenic | D | Supports Oncogenicity | 4 | submitted | EID10172A 52-year-old Caucasian male with second relapsed B-ALL following chemotherapy and blinatumomab (NCT02013167). BMA obtained at study entry on the INOVATE trial (NCT01564784) was analyzed by RNA-seq an… (full text at CIViC) PMID 34991158 · Iacobucci et al., 2022 · Open in CIViC | civic |
| JAK2 Fusion1 | ||||||||
| Ruxolitinib | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID7007A 10-year-old Caucasian boy with high risk B-cell acute lymphoblastic leukemia failed induction therapy. The patient had a complex karyotype and microarray revealed a 9p duplication involving JAK2 and… (full text at CIViC) PMID 29773603 · Ding et al., 2018 · Open in CIViC | civic |
| CRLF2 Fusion4 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | B | Supports Positive | 5 | accepted | EID11613The authors performed genomic profiling of 1725 cases of B-lymphoblastic leukemia/lymphoma (B-ALL). Overall, 264 of 1725 B-ALL cases (15.3%) were identified as BCR::ABL1 (Ph)-like based on their expr… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| (prognostic) | Adult B Acute Lymphoblastic LeukemiaALIAS | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID7212CRLF2 overexpression was examined in 90 adult B-ALL patients with demographic data that lacked characteristic rearrangements and identified overexpression in 15/90 (16.67%). Disease-free survival was … (full text at CIViC) PMID 20018760 · Yoda et al., 2010 · Open in CIViC | civic |
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | |||||
| CRLF2 Fusion + JAK2 R683GCRLF2JAK21 | ||||||||
| Sirolimus | B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1ALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID7641Xenografts were established from Ph-like ALL patient derived cells harboring CRLF2 rearrangements and JAK2 mutations. A xenograft with a JAK2 R683G mutation and IGH-CRLF2 rearrangement showed signific… (full text at CIViC) PMID 22955920 · Maude et al., 2012 · Open in CIViC | civic |
| DUX4 Fusion5 | ||||||||
| (diagnostic) | B Acute Lymphoblastic Leukemia with DUX4 RearrangementALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12248This study identifies DUX4 rearrangements, specifically IGH::DUX4 fusions, as diagnostic markers for a distinct molecular subtype of Philadelphia chromosome-negative (Ph−) B-lymphoblastic leukemia/lym… (full text at CIViC) PMID 27019113 · Yasuda et al., 2016 · Open in CIViC | civic |
| 〃 | B Acute Lymphoblastic Leukemia with DUX4 RearrangementALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12249This study highlights the diagnostic significance of DUX4 gene rearrangements in a distinct molecular subtype of B-lymphoblastic leukemia/lymphoma (B-ALL). Among 1,913 B-ALL cases, including 1,347 chi… (full text at CIViC) PMID 27776115 · Zhang et al., 2016 · Open in CIViC | civic |
| 〃 | B Acute Lymphoblastic Leukemia with DUX4 Rearrangement | |||||||
| EPOR Fusion4 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | B | Supports Positive | 4 | accepted | EID12395This MD Anderson Cancer Center study describes six adult patients (3 males and 3 females, median age 39 yo) with t(14;19)(q32;p13) resulting in IGH::EPOR. 3 patients did not receive any prior chemothe… (full text at CIViC) PMID 24030742 · Jaso et al., 2014 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 4 | accepted | EID12393In this 2024 case report the authors describe a case of BCR::ABL1-like B-ALL with unusual granular morphology in a female patient, 12 year old, with the following symptoms: paroxysmal headache, vomiti… (full text at CIViC) PMID 38302862 · Long et al., 2024 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports | ||||
| IL3 Fusion3 | ||||||||
| (diagnostic) | B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGHALIAS | Diagnostic | B | Supports Positive | 3 | accepted | EID12243In this 2019 study, the authors included 8 patients with B-ALL presenting with t(5;14)(q31;q32) and reviewed another 16 patients from the literature. The median age at onset was 14.3 years (range of 4… (full text at CIViC) PMID 31921638 · Fournier et al., 2019 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGHALIAS | Diagnostic | C | Supports Positive | 4 | accepted | EID12244In this 2021 study the authors include four B-ALL cases with an IGH::IL3 gene fusion that initially were unable to be fully characterized by conventional methods. Patients' ages ranged from 6 to 19 ye… (full text at CIViC) PMID 33991782 · Guenzel et al., 2021 · Open in CIViC | civic |
| 〃 | ||||||||
| IKZF1 Deletion6 | ||||||||
| (prognostic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | A | Supports Poor Outcome | 5 | accepted | EID7365This prospective study reports the prognosis of patients with B-ALL and an IKZF1 deletion and the impact of intensification of treatment in this subgroup. In 50 patients from the MS2003 cohort, the 5-… (full text at CIViC) PMID 30044693 · Yeoh et al., 2018 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | A | Supports Poor Outcome | 5 | accepted | EID7404A meta-analysis of 15 published studies including 5021 patients with B-ALL showed that IKZF1 had an unfavorable impact on event-free survival (HR=2.32) and overall survival (HR=2.56). The correlation … (full text at CIViC) PMID 25335741 · Jia et al., 2014 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma | |||||||
Data updated 16 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| 3 |
| accepted |
EID8097In B-lymphoblastic leukemia/lymphoma (B-ALL), the presence of this fusion is associated with so-called BCR/ABL1 like (Ph-like) subtype of the disease. In this study involving 798 B-ALL patients of whi… (full text at CIViC) PMID 27870571 · Roberts et al., 2017 · Open in CIViC |
| civic |
| Predictive |
| C |
| Supports Sensitivity Response |
| 3 |
| accepted |
EID7993Case report of a 61-year-old man with B-ALL. An initial analysis detected the ETV6-NTRK3 fusion and a NRASGly12Asp mutation. Initial therapies included chemotherapy and CAR-T infusion. Relapse 6 weeks… (full text at CIViC) PMID 31905241 · Nardi et al., 2020 · Open in CIViC |
| civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID6930Both in vivo and in vitro models demonstrated Larotrectinib was an effective treatment against cells harboring ETV6-NTRK3. In YFP-luciferase PDX mice from a 16-year-old with Ph-like B-ALL, flow cytome… (full text at CIViC) PMID 29880614 · Roberts et al., 2018 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID8930Conventional cytogenetics, FISH, and an Abbott break-apart probe of a peripheral blood sample collected at diagnosis of a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute… (full text at CIViC) PMID 31725893 · Schewe et al., 2019 · Open in CIViC | civic |
| Etoposide + Larotrectinib + MethotrexateCombination | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID8917All lines of conventional therapy (including allogeneic HSCT, blinatumomab, and CAR T cells) were inefficient for a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute high … (full text at CIViC) PMID 31725893 · Schewe et al., 2019 · Open in CIViC | civic |
| B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1ALIAS |
| Diagnostic |
| B |
| Supports Positive |
| 4 |
| accepted |
EID12375In this study, the authors investigated the t(12;21)(p13;q22) in pediatric acute lymphoblastic leukemia (ALL). The t(12;21) is typically not visible by karyotype analysis and is rarely detected by con… (full text at CIViC) PMID 8609706 · Shurtleff et al., 1995 · Open in CIViC |
| civic |
| Not Applicable | B Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1ALIAS | Predictive | B | Supports Adverse Response | 4 | accepted | EID12374In this study, the authors characterized the TEL (currently ETV6)::AML1 (currently RUNX1) gene fusion in B-lymphoblastic leukemia (B-ALL) with the t(12;21)(p12;q22) using cytogenetic and molecular met… (full text at CIViC) PMID 7780150 · Romana et al., 1995 · Open in CIViC | civic |
| Predictive |
| C |
| Supports Sensitivity Response |
| 2 |
| submitted |
EID12566A previously healthy 2-year-old girl presented with right supraorbital swelling, hepatosplenomegaly, anemia (Hb 8.2 g/dl) and leukocytosis (WBC 19.5 × 109/L) with eosinophilia of 32% and an absolute e… (full text at CIViC) PMID 36589160 · Akiely et al., 2022 · Open in CIViC |
| civic |
| 1 |
| accepted |
EID11615B-lymphoblastic leukemia/lymphoma (B-ALL) cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine BCR::ABL1-like… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC |
| civic |
| (prognostic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | D | Supports Poor Outcome | 4 | rejected | EID9154This study comprised 127 consecutive patients (age ≥16 years) with newly diagnosed BCP-ALL with available molecular data.The non-response rate, defined as the proportion of patients who had not achiev… (full text at CIViC) PMID 25769542 · Boer et al., 2015 · Open in CIViC | civic |
| Dasatinib | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID7292A 16-year-old Caucasian boy was diagnosed with B-lymphoblastic leukemia (B-ALL). Karyotype showed an abnormal clone characterized by the t(3;9)(p13;q34.1). This translocation has been shown previously… (full text at CIViC) PMID 30938769 · Yenamandra et al., 2019 · Open in CIViC | civic |
| Supports Positive |
| 4 |
| accepted |
EID8233Among 284 cases with Ph-like expression signature who were identified by testing 1389 high-risk cases of pediatric B-ALL, overexpression and rearrangement of CRLF2 were identified in 124 (43.7%). This… (full text at CIViC) PMID 28408464 · Reshmi et al., 2017 · Open in CIViC |
| civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 2 | accepted | EID11621B-ALL cases with high-risk clinical features or suggestion of a kinase rearrangement were subjected to low density gene expression array to determine Ph-like status. 2 patients (ages 7.6 and 16.3 yea… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC | civic |
| Diagnostic |
| B |
| Supports Positive |
| 4 |
| accepted |
EID12250In this study, the authors analyzed the fusion gene landscape in pediatric B-lymphoblastic leukemia (B-ALL) across 195 cases using RNA sequencing. Fusion genes were identified in 127 cases (65%), incl… (full text at CIViC) PMID 27265895 · Lilljebjörn et al., 2016 · Open in CIViC |
| civic |
| 〃 | B Acute Lymphoblastic Leukemia with DUX4 RearrangementALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12251This study highlights the diagnostic significance of DUX4 rearrangements in identifying a distinct molecular subtype of B-lymphoblastic leukemia/lymphoma (B-ALL). Using transcriptome sequencing of 1,9… (full text at CIViC) PMID 30643249 · Gu et al., 2019 · Open in CIViC | civic |
| (oncogenic) | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Oncogenic | C | Supports Oncogenicity | 3 | submitted | EID7027Insertion of D4Z4 repeats containing the DUX4 gene into the IGH locus was frequently identified in B cell AYA-ALL, leading to a high level of expression of DUX4 protein with an aberrant C terminus. DU… (full text at CIViC) PMID 27019113 · Yasuda et al., 2016 · Open in CIViC | civic |
| 4 |
| accepted |
EID12394This is a case report from MD Anderson Cancer Center. A 40yo Caucasian male patient was diagnosed with B-ALL with IGH::EPOR fusion. The patient received 4 cycles of R-hyper-CVAD and archived CR with M… (full text at CIViC) PMID 32330662 · Liu et al., 2020 · Open in CIViC |
| civic |
| 〃 | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | Diagnostic | C | Supports Positive | 4 | accepted | EID12396This 2021 study reports 3 adolescent/young adult patients with IGH::EPOR-positive B-ALL treated with post-induction chemotherapy combined with JAKi ruxolitinib or TKI ponatinib. Patient 1 was hispanic… (full text at CIViC) PMID 34196168 · Niswander et al., 2021 · Open in CIViC | civic |
| B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGHALIAS |
| Diagnostic |
| C |
| Supports Positive |
| 2 |
| accepted |
EID12245In this 1989 study the authors analyzed the bone marrow aspirate from a B-ALL patient presenting with eosinophilia in the peripheral blood and found to have the t(5;14)(q31;q32) chromosomal translocat… (full text at CIViC) PMID 2499362 · Grimaldi et al., 1989 · Open in CIViC |
| civic |
| Prognostic |
| B |
| Supports Poor Outcome |
| 4 |
| accepted |
EID484In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, those with deletions of IKZF1 had worse event-free and overall survival than patients without deletions (N=68 vs 13… (full text at CIViC) PMID 22699455 · Krentz et al., 2013 · Open in CIViC |
| civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID629In patients with Philadelphia Chromosome negative B-cell precursor acute lymphoblastic leukemia, focal deletion involving 3-5 exons of IKZF1 was associated with higher cumulative incidence of relapse … (full text at CIViC) PMID 24740809 · Beldjord et al., 2014 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID7532A meta-analysis of 8 published studies including 1008 adult patients (all patients were >14 years old) with B-ALL showed that IKZF 1 deletion had a negative impact on overall survival (HR=1.4, 95% CI … (full text at CIViC) PMID 27815723 · Zhang et al., 2017 · Open in CIViC | civic |
| 〃 | B Lymphoblastic Leukemia/LymphomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID624IKZF1 deletions are associated with poor outcome in patients with childhood BCR-ABL–positive B-cell precursor acute lymphoblastic leukemia even when treated with imatinib. This phenomenon was observed… (full text at CIViC) PMID 24366361 · van der Veer et al., 2014 · Open in CIViC | civic |